Repositorio Dspace

Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)

Mostrar el registro sencillo del ítem

dc.contributor.author Carnero Contentti, Edgar
dc.contributor.author Lopez, Pablo A.
dc.contributor.author Patrucco, Liliana
dc.contributor.author Cristiano, Edgardo
dc.contributor.author Miguez, Jimena
dc.contributor.author Silva, Berenice
dc.contributor.author Liwacki, Susana
dc.contributor.author Tkachuk, Verónica
dc.contributor.author Balbuena Aguirre, María Eugenia
dc.contributor.author Vrech, Carlos
dc.contributor.author Deri, Norma
dc.contributor.author Correale, Jorge
dc.contributor.author Marrodán, Mariano
dc.contributor.author Ysrraelit, María Célica
dc.contributor.author Fiol, Marcela Paula
dc.contributor.author Leguizamon, Felisa
dc.contributor.author Luetic, Geraldine
dc.contributor.author Tavolini, Darío
dc.contributor.author Mainella, Carolina
dc.contributor.author Zanga, Gisela
dc.contributor.author Burgos, Marcos
dc.contributor.author Hryb, Javier
dc.contributor.author Barboza, Andrés
dc.contributor.author Lazaro, Luciana
dc.contributor.author Alonso, Ricardo
dc.contributor.author Fernández Liguori, Nora
dc.contributor.author Nadur, Débora
dc.contributor.author Martínez, Alejandra
dc.contributor.author Steinberg, Judith
dc.contributor.author Carrá, Adriana
dc.contributor.author Alonso Serena, Marina
dc.contributor.author Rojas, Juan I.
dc.date.accessioned 2024-08-26T14:48:03Z
dc.date.available 2024-08-26T14:48:03Z
dc.date.issued 2024-09
dc.identifier.citation Carnero Contentti E, Lopez PA, Patrucco L, Cristiano E, Miguez J, Silva B, Liwacki S, Tkachuk V, Balbuena ME, Vrech C, Deri N, Correale J, Marrodan M, Ysrraelit MC, Fiol M, Leguizamon F, Luetic G, Tavolini D, Mainella C, Zanga G, Burgos M, Hryb J, Barboza A, Lazaro L, Alonso R, Fernández Liguori N, Nadur D, Martinez A, Steinberg J, Carrá A, Alonso Serena M, Rojas JI. Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM). Mult Scler Relat Disord. 2024 Sep;89:105771. doi: 10.1016/j.msard.2024.105771. Epub 2024 Jul 20. es_ES
dc.identifier.uri https://doi.org/10.1016/j.msard.2024.105771
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/1195
dc.description.abstract Background: Immunosuppressive therapies as azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX) are widely prescribed as first-line treatment to prevent relapses in NMOSD. However, the rate of response to these traditional therapies is unknown in Argentina. We aimed to describe and compare treatment failure rates in NMOSD patients included in the Argentinean MS and NMOSD registry (RelevarEM, NCT03375177). Methods: A retrospective cohort study was conducted in NMOSD patients included in RelevarEM (a nationwide, longitudinal, observational, non-mandatory registry of MS and NMOSD in Argentina). NMOSD patients were defined based on validate diagnostic criteria. Only NMOSD patients who received AZA or MMF for at least 6 months or RTX for at least 1 month were included. Patients who were receiving AZA, MMF, or RTX and then switched to another 1 of these 3 therapies were included if the above-mentioned criteria for each drug were fulfilled. Data on patient demographics, clinical, neuroradiological findings, and treatments administered were collected. Treatment failure was defined as any new attack/relapse that occurred despite immunosuppressive treatment. Results: We included 139 NMOSD patients who were receiving AZA (n = 105), MMF (n = 5) or RTX (n = 29) with a mean follow-up time of 41.3 ± 11.4 months and median of EDSS at treatment initiation of 3. We observed a reduction in the annualized relapse rate from pre-treatment to post-treatment of 51.1 %, 48.4 %, and 79.1 % respectively with a Hazard Risk relative to RTX (95 % CI) of 1.67 (1.34-3.54, p = 0.01) for AZA and 2.01 (1.86-4.43, p = 0.008) for MMF. AZA, MMF and RTX failure was observed in 45/105 (42.8 %), 2/5 (40 %) and 3/29 (10.3 %) patients, respectively. Conclusions: Treatment failure rates were higher for AZA and MMF than RTX in Argentinean NMOSD patients in a real-world setting. High-efficacy treatment increases the opportunity to prevent attacks of NMOSD. es_ES
dc.language.iso eng es_ES
dc.publisher Elsevier es_ES
dc.subject Neuromielitis Óptica es_ES
dc.subject Neuromyelitis Optica es_ES
dc.subject Argentina es_ES
dc.subject Terapéutica es_ES
dc.subject Therapeutics es_ES
dc.subject Multiple Sclerosis
dc.subject Esclerosis Múltiple
dc.title Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM) es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.description.fil Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.
dc.description.fil Fil: Marrodán, Mariano. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.
dc.description.fil Fil: Ysrraelit, María Célica. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.
dc.description.fil Fil: Fiol, Marcela Paula. Fleni. Departamento de Neurología; Argentina.
dc.relation.ispartofVOLUME 89
dc.relation.ispartofPAGINATION 105771
dc.relation.ispartofCOUNTRY Países Bajos
dc.relation.ispartofCITY Ámsterdam
dc.relation.ispartofTITLE Multiple sclerosis and related disorders
dc.relation.ispartofISSN 2211-0356
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Listar

Mi cuenta

Estadísticas